The artificial intelligence healthcare firm Healwell AI has reported staggering revenue growth, according to recent disclosures from its majority partner, WELL Health Technologies. WELL Health’s annual report, released on March 19, 2026, revealed that Healwell AI generated CAD 32.2 million in sales during the fourth quarter of 2025. This figure represents a monumental 374% increase compared to the same period in the prior year.
A Pillar of Broader Success
This explosive performance positioned Healwell AI as a primary growth engine within WELL Health’s digital health services division. The parent company itself announced record annual revenue for the full year 2024, surpassing CAD 1.4 billion. This marked a substantial 52% year-over-year gain for the consolidated entity.
Infrastructure development provides further momentum. WELLSTAR, a subsidiary, now operates a national billing and administrative platform across six Canadian provinces. This platform manages more than 4.3 million patient visits annually, a volume that has surged by 37% from the previous year. The expanding dataset derived from this operational scale directly enhances the machine learning algorithms powering Healwell AI’s diagnostic and preventative tools.
In a strategic move to deepen clinical integration, February 2026 saw the launch of WELLTRUST. This joint initiative with WELL Health is designed to embed AI directly into clinical workflows, aiming to boost operational efficiency and improve patient safety outcomes.
Should investors sell immediately? Or is it worth buying Healwell AI?
Future Trajectory and Acquisition Strategy
Looking ahead, management has provided guidance for the 2026 fiscal year. WELL Health anticipates consolidated revenue in the range of CAD 1.55 billion to CAD 1.65 billion. Adjusted EBITDA is projected to land between CAD 175 million and CAD 185 million.
A significant portion of this anticipated growth is underpinned by a robust acquisition pipeline linked to Healwell AI. The company currently has letters of intent for clinic acquisitions representing approximately CAD 260 million in annual revenue. Furthermore, additional potential acquisition targets, with a combined revenue exceeding CAD 455 million, are under active review. Each new integration not only adds scale but also enriches the foundational data pool essential for training and refining the AI platform.
Despite this powerful operational momentum, market sentiment appears to have already priced in high expectations. The equity currently trades approximately 55% below its 52-week high, which was recorded in March 2025.
Ad
Healwell AI Stock: Buy or Sell?! New Healwell AI Analysis from March 22 delivers the answer:
The latest Healwell AI figures speak for themselves: Urgent action needed for Healwell AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 22.
Healwell AI: Buy or sell? Read more here...
